title: Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine era.
abstract: Prior to the introduction of Haemophilus influenzae type b (Hib) conjugate vaccines, invasive Hib disease affected almost exclusively children. According to some recent studies, in the postvaccine era, adults, the elderly, and immunocompromised persons can be affected more often than children. As the production of type-specific anti-capsular polysaccharide antibodies is the major defense mechanism against Hib, individuals with defects in humoral immune responses have high susceptibility to infections caused by Hib. We hypothesized that nonvaccinated adults with chronic conditions causing immunosuppression may lack protective antibody to Hib. We assessed serum anti-Hib IgG levels and bactericidal activity in 59 patients with chronic renal failure, 30 patients with type 2 diabetes mellitus, 28 patients with chronic obstructive pulmonary disease (COPD), and 20 patients with multiple myeloma compared to 32 healthy controls of similar age. Considering antibody at >0.15 μg/ml as the protective correlate in unvaccinated individuals, we detected subprotective Hib antibody levels in 29% of chronic renal failure, 20% of diabetes, 14% of COPD, and 55% of myeloma patients compared to 3% of healthy controls. Additionally, 70% of myeloma and 58% of chronic renal failure patients did not have detectable serum bactericidal activity against Hib. Among individuals with severe diseases causing secondary immunodeficiency, patients with multiple myeloma and chronic renal failure are at an increased risk of invasive Hib disease. Considering that Hib continues to circulate in the population, this study provides a rationale for the immunization of some adult patients with secondary immunodeficiency with the pediatric Hib vaccine to achieve protective immunity.
authors.affiliation: Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Ontario, Canada.
authors.forename: Eli B
authors.initials: EB
authors.lastname: Nix
authors.forename: Nicole
authors.initials: N
authors.lastname: Hawdon
authors.forename: Sean
authors.initials: S
authors.lastname: Gravelle
authors.forename: Birubi
authors.initials: B
authors.lastname: Biman
authors.forename: Malcolm
authors.initials: M
authors.lastname: Brigden
authors.forename: Saleem
authors.initials: S
authors.lastname: Malik
authors.forename: William
authors.initials: W
authors.lastname: McCready
authors.forename: Garry
authors.initials: G
authors.lastname: Ferroni
authors.forename: Marina
authors.initials: M
authors.lastname: Ulanova
mesh_terms: D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D016667:Bacterial Capsules / Q000008:administration & dosage / Q000276:immunology; D001770:Blood Bactericidal Activity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D006192:Haemophilus Infections / Q000453:epidemiology / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D051437:Renal Insufficiency / Q000150:complications; D018570:Risk Assessment
chemical_list: D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D007074:Immunoglobulin G